Tags : IV

GSK Reports Results of Benlysta (belimumab, IV) in P-III BLISS-LN

Shots: The P-III BLISS-LN study involves assessing of IV belimumab 10 mg/kg + standard therapy vs PBO in 448 patients with active lupus nephritis for 104 wks. P-III BLISS-LN study results: met 1EPs and all major 2EP; Primary Efficacy Renal Response (PERR) (43% vs 32%); showed consistent safety results; ORR was defined as complete   […]Read More